静脉对乙酰氨基酚与静脉或肌注非甾体抗炎药或阿片类药物治疗急诊中度至重度急性疼痛的比较:系统评价与荟萃分析
该系统评价与荟萃分析检索PubMed(MEDLINE)、Web of Science、Embase(OVID)、Cochrane Library、SCOPUS和Google Scholar(2021年3月3日至2022年5月20日)的随机试验,纳入27项试验(5427例患者),其中25项试验(5006例患者)进入荟萃分析,比较静脉对乙酰氨基酚单药与静脉或肌注NSAIDs或静脉阿片类药物在急诊成人急性疼痛中的镇痛效果。主要终点给药后30分钟疼痛减轻的平均差(MD)在静脉对乙酰氨基酚组与阿片类组(MD -0.13,95%CI -1.49至1.22)及与NSAIDs组(MD -0.27,95%CI -1.0至1.54)间均无显著差异;60分钟亦无差异。静脉对乙酰氨基酚组30分钟需补救镇痛的风险显著高于NSAIDs组(RR 1.50,95%CI 1.23至1.83),与阿片类组无差异(RR 1.07,95%CI 0.67至1.70);不良事件静脉对乙酰氨基酚组较阿片类组低50%(RR 0.50,95%CI 0.40至0.62),与NSAIDs组无差异(RR 1.30,95%CI 0.78至2.15)。作者认为NSAIDs可作为首选镇痛,静脉对乙酰氨基酚为合适替代。
要点
- 急诊中度至重度急性疼痛成人中,静脉对乙酰氨基酚与阿片类30分钟疼痛减轻MD -0.13(95%CI -1.49至1.22),与NSAIDs MD -0.27(95%CI -1.0至1.54),均无显著差异。
- 60分钟疼痛减轻静脉对乙酰氨基酚组与阿片类组MD -0.09(95%CI -2.69至2.52),与NSAIDs组MD 0.51(95%CI 0.11至0.91)。
- 30分钟需补救镇痛静脉对乙酰氨基酚组显著高于NSAIDs组(RR 1.50,95%CI 1.23至1.83),与阿片类组无差异(RR 1.07,95%CI 0.67至1.70)。
- 不良事件静脉对乙酰氨基酚组较阿片类组低50%(RR 0.50,95%CI 0.40至0.62),与NSAIDs组无差异(RR 1.30,95%CI 0.78至2.15)。
- 作者认为NSAIDs可作为首选镇痛,静脉对乙酰氨基酚为合适替代;疼痛评分MD证据质量低(GRADE)。
适用人群与场景
- 到急诊就诊的成人(年龄≥18岁)中度至重度急性疼痛患者,疼痛病因多样。
处置流程与药物剂量
- 作者认为NSAIDs可作为急诊中度至重度急性疼痛的首选镇痛。
- 作者认为静脉对乙酰氨基酚可作为NSAIDs的合适替代镇痛。
研究设计与关键结果
- 系统评价与荟萃分析,纳入27项随机试验(5427例患者),其中25项试验(5006例患者)进入荟萃分析;检索PubMed(MEDLINE)、Web of Science、Embase(OVID)、Cochrane Library、SCOPUS和Google Scholar(2021年3月3日至2022年5月20日),无语言或日期限制。
- 主要终点给药后30分钟疼痛减轻MD:静脉对乙酰氨基酚组 vs 阿片类组 MD -0.13(95%CI -1.49至1.22),无显著差异;静脉对乙酰氨基酚组 vs NSAIDs组 MD -0.27(95%CI -1.0至1.54),无显著差异。
- 60分钟疼痛减轻MD:静脉对乙酰氨基酚组 vs 阿片类组 MD -0.09(95%CI -2.69至2.52),无显著差异;静脉对乙酰氨基酚组 vs NSAIDs组 MD 0.51(95%CI 0.11至0.91)。
- 30分钟需补救镇痛:静脉对乙酰氨基酚组显著高于NSAIDs组(RR 1.50,95%CI 1.23至1.83);静脉对乙酰氨基酚组与阿片类组无差异(RR 1.07,95%CI 0.67至1.70)。
- 不良事件:静脉对乙酰氨基酚组较阿片类组低50%(RR 0.50,95%CI 0.40至0.62);静脉对乙酰氨基酚组与NSAIDs组无差异(RR 1.30,95%CI 0.78至2.15)。
- 采用GRADE方法评价,疼痛评分MD的证据质量低。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析(纳入随机试验)。
- 疼痛评分MD的证据质量采用GRADE方法评价为低。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于急诊中度至重度急性疼痛成人,NSAIDs可作为首选镇痛,静脉对乙酰氨基酚为合适替代。
- 静脉对乙酰氨基酚30分钟需补救镇痛的风险显著高于NSAIDs(RR 1.50,95%CI 1.23至1.83),临床选择镇痛方案时需考虑此差异。
- 静脉对乙酰氨基酚不良事件较阿片类低50%(RR 0.50,95%CI 0.40至0.62),在阿片类相关不良事件风险较高的患者中可能具有优势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opiates/opioids, administered parenterally via intravenous or intramuscular route, are widely used to provide analgesia for patients with moderate to severe pain. This systematic review and meta-analysis evaluated the level of analgesia provided by intravenous paracetamol (IVP) alone compared with NSAIDs (intravenous or intramuscular), or opioids (intravenous) alone in adults attending the ED with acute pain.
METHODS: Two authors independently searched PubMed (MEDLINE), Web of Science, Embase (OVID), Cochrane Library, SCOPUS and Google Scholar (3 March 2021-20 May 2022) for randomised trials without any language or date restriction. Clinical trials were evaluated using the Risk of Bias V.2 tool. The primary outcome was mean difference (MD) for pain reduction at 30 min (T30) post analgesia delivery. The secondary outcomes were MD in pain reduction at 60, 90 and 120 min; the need for rescue analgesia; and the occurrence of adverse events (AEs).
RESULTS: Twenty-seven trials (5427 patients) were included in the systematic review and 25 trials (5006 patients) in the meta-analysis. There was no significant difference in pain reduction at T30 between the IVP group and opioids (MD -0.13, 95% CI -1.49 to 1.22) or IVP and NSAIDs (MD -0.27, 95% CI -1.0 to 1.54. There was also no difference at 60 min, IVP group versus opioid group (MD -0.09, 95% CI -2.69 to 2.52) or IVP versus NSAIDs (MD 0.51, 95% CI 0.11 to 0.91). The quality of the evidence using Grading of Recommendations, Assessments, Development and Evaluations methodology was low for MD in pain scores.The need for rescue analgesia at T30 was significantly higher in the IVP group compared with the NSAID group (risk ratio (RR): 1.50, 95% CI 1.23 to 1.83), with no difference found between the IVP group and the opioid group (RR: 1.07, 95% CI 0.67 to 1.70). AEs were 50% lower in the IVP group compared with the opioid group (RR: 0.50, 95% CI 0.40 to 0.62), whereas no difference was observed in the IVP group compared with the NSAID group (RR: 1.30, 95% CI 0.78 to 2.15).
CONCLUSION: In patients presenting to the ED with a diverse range of pain conditions, IVP provides similar levels of pain relief compared with opiates/opioids or NSAIDs at T30 post administration. Patients treated with NSAIDs had lower risk of rescue analgesia, and opioids cause more AEs, suggesting NSAIDs as the first-choice analgesia and IVP as a suitable alternative.
PROSPERO REGISTRATION NUMBER: CRD42021240099.
参考来源
- Qureshi I, Abdulrashid K, Thomas SH, et al. Comparison of intravenous paracetamol (acetaminophen) to intravenously or intramuscularly administered non-steroidal anti-inflammatory drugs (NSAIDs) or opioids for patients presenting with moderate to severe acute pain conditions to the ED: systematic review and meta-analysis. Emerg Med J. 2023. PMID: 37173122. doi:10.1136/emermed-2022-212869
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。